fluvastatin

Known as: 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate, fluindostatin, fluvastatin [Chemical/Ingredient] 
A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2018
05010019902018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND Adverse cardiac events are common after vascular surgery. We hypothesized that perioperative statin therapy would… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The purpose of this study is to determine the biologic impact of short-term lipophilic statin exposure on in situ and invasive… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUNDHepatitis C viral (HCV) infection is the leading cause of death due to liver disease in the United States. Currently… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Renal transplant recipients (RTR) have an increased risk of premature cardiovascular disease. The ALERT study is the first trial… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Renal transplant recipients are at increased risk of premature cardiovascular disease. Although statins reduce… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
CONTEXT Percutaneous coronary intervention (PCI) is associated with excellent short-term improvements in ischemic symptoms, yet… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Short-term administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, has been… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Statins reduce cardiovascular events and progression of carotid intima-media thickness (IMT). beta-Blockers are also… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Studies in vitro reveal that fluvastatin, an HMG-CoA reductase inhibitor, has a strong DPPH radical scavenging activity and… (More)
Is this relevant?